Please subscribe, like and comment on our videos to show support for EGA, the free way to say thanks 😊🍄🌵 -- Bios -- Martin Williams, PhD is a Senior Research Fellow at the Centre for Mental Health, Swinburne University. His research background is in Medicinal Chemistry and Pharmacology. Martin is a co-investigator on a number of Australian clinical trials of psychedelic-assisted psychotherapy, including the St Vincent’s Hospital Melbourne study of psilocybin-assisted psychotherapy in palliative care; the Monash PsiConnect neuroimaging study of psilocybin with mindfulness meditation; the Swinburne pilot study and 3PAP RCT of 2- vs 3-dose psilocybin-assisted therapy for depression; and several other studies of psilocybin, MDMA and other psychedelics for the treatment of a range of mental health conditions. Prash Puspanathan, a medical doctor and former Neuropsychiatry Fellow at The Alfred Hospital in Melbourne, is one of Australia’s leading advocates for accessible psychedelic-assisted psychotherapy. In this capacity, Prash is a clinical adviser to the Australian Psychedelic Society and is frequently sought for his thought leadership on the subject of the therapeutic uses of psychedelic substances. Prash has a Bachelor of Medicine and Bachelor of Surgery (Honours) from Monash University in Melbourne, a Masters in Psychological Medicine from the University of Melbourne, and has written for a number of publications including The Lancet and the Australian & New Zealand Journal of Psychiatry. Lily Kay Ross is a journalist, harm reduction advocate, and independent scholar advancing the field of Critical Psychedelic Studies. She’s Creator and Producer of New York magazine’s Cover Story: Power Trip podcast. She’s interested in queer, feminist and neurodivergent perspectives, peer-reviewed research, and science journalism that centers patients and people with lived experience. She has her Masters of Divinity from Harvard, and her PhD in Gender Studies from the University of Otago. Lily was Feminism & Ethics Research Fellow and Producer at Psymposia from 2020 until her resignation in 2023. Website - https://secondhallway.com/ David Nickles is an underground researcher, harm reduction advocate, and journalist. He’s Creator and Producer of New York magazine’s Cover Story: Power Trip Podcast. As a forerunner of Critical Psychedelic Studies, his work has focused on the intersection of radical politics and the sociocultural implications of psychoactive substances, research and clinical ethics, and novel phytochemical analysis of psychoactive materials. He is a vocal opponent of psychedelic commodification and blows glass in an idealistic attempt to avoid monetizing his psychedelic work. After five years with the organization, Dave resigned from his role as Managing Editor of Psymposia at the end of 2023. Website - https://secondhallway.com/ Samuel Banister is cofounder and Chief Scientific Officer at Xylo Bio; a biotech start-up focused on the development of next-generation psychedelic-inspired medicines. Sam has been developing new therapeutics in the fields of psychiatry and neurology for more than 15 years at leading academic institutions (Stanford University, University of Sydney, UNSW) and biotech start-ups (Tranquis Therapeutics, Nalu Bio, Pangea Botanica). Prior to cofounding Xylo Bio, he was Team Leader in Medicinal Chemistry at The Lambert Initiative for Cannabinoid Therapeutics, and before that was a postdoc at Stanford University developing PET tracers for neuroinflammation, exploring new therapeutic targets for neurodegeneration, and profiling new psychoactive substances (NPS). Shaun Duffy is the CEO and Managing Director of Reset Mind Sciences, a company focused on the use of psychedelic medicines to treat mental health. Shaun has overseen the establishment of Reset Mind Sciences and its entry into the field of psychedelics including fully licensed and regulatory approved mushroom cultivation and ethics approval for Western Australia’s first psilocybin based clinical trial. Shaun is a former Senior Managing Director of FTI Consulting as well as head of that firm’s Australian Strategic Communications practice and member of its Australian Leadership Group. 00:00 - Introduction & Speaker Bios 01:03 - Why This Panel Discussion? 02:44 - From Science to Industry: Psychedelics & Capital 05:19 - Panelist Introductions 10:51 - Ethics & Capital in Psychedelics 16:08 - Regulatory Capture & Big Pharma Influence 19:20 - The Role of Corporate vs. Small Pharma 24:36 - Investment Trends in Psychedelics 30:48 - Non-Hallucinogenic Psychedelics: Opportunity or Threat? 36:12 - Challenges in Psychedelic Therapy Standardization 42:47 - Medicalization vs. Decriminalization Debate 46:01 - The Case of Ketamine Therapy & At-Home Models 51:07 - The Need for More Expertise in Psychedelics 55:56 - Final Thoughts & Closing Remarks
Emerging research around psilocybin-assisted psychotherapy, drug law reform, ecological sustainability, harm reduction and mycological research all intersect with the needs and values of our ethnobotanical community. Please subscribe, like and comment on our videos to show support for EGA - This is a free way to say thank you to our charity 😊🍄🌵- www.entheogenesis.org Enjoy this playlist at the myceliating edge of psychedelic fungi. Featuring Dr Vince Polito, Dr Shevaugn Johnson, Dr Symon Beck, journalist Rich Haridy, mycologist Caine Barlow, Horticultural Science Alistair Mctaggart. Thanks to our regular host Nick Wallis ---- About EGA. Entheogenesis Australis is a charitable educational organisation established in 2004. We provide opportunities for critical thinking and knowledge sharing on ethnobotanical plants, fungi, nature, and sustainability. Through our conferences and workshops, we aim to celebrate the culture, art, politics and community around medicine plants in the hope to better wellbeing for humankind and the planet. To find out more about what we do, head over to our organisational website - www.entheogenesis.org Also, head to the conference website for more info - www.gardenstates.org